Novartis Malaria Initiative: Best practice example of pharmaceutical industry's engagement in the fight against malaria

Annals of the New York Academy of Sciences

Volumn 1222, Issue 1, 2011, Pages 19-29

  Lefèvre, Gilbert ^a   Marrast, Anne Claire ^a   Grueninger, Heiner ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Artemether lumefantrine; Artemisinin based combination therapy; Dispersible; Malaria

Indexed keywords

AMODIAQUINE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; CHLOROQUINE; DAPSONE; DIHYDROARTEMISININ; PIPERAQUINE; PYRIMETHAMINE; SULFADOXINE;

AREA UNDER THE CURVE; ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MALARIA; MALARIA CONTROL; NEUROLOGIC DISEASE; NONHUMAN; PLASMODIUM FALCIPARUM; TABLET FORMULATION;

PLASMODIUM FALCIPARUM;

EID: 79952843993     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05973.x     Document Type: Article

References (80)

1. WHO Guidelines for the Treatment of Malaria: second Edition (2010).
2. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. 22-11-2010.
3. ® International Package Leaflet. 2010.
4. US Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States. (Based on drugs currently available for use in the United States - updated May 18, 2009). 18-5-2009.
5. ® Basic Prescribing Information. 28-5-2009.
6. WHO Prequalified Medicines List. 2010.
7. WHO. WHO Model List of Essential Medicines. 2010.
8. WHO. WHO Model List of Essential Medicines for Children. 2010.
9. Abdulla, S., I. Sagara, S. Borrmann, et al 2008. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 372: 1819-1827.
10. Report to WHO concerning international guidelines for paediatric medicines. 2010. Paediatric Regulators Network Meeting, Geneva, 15-17 February 2010.
11. Abdulla, S., B. Amuri, A.M. Kabanywanyi, et al 2010. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar. J. 9: 253.
12. White, N.J., M. van Vugt & F. Ezzet 1999. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37: 105-125.
13. Kokwaro, G., L. Mwai & A. Nzila 2007. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert. Opin. Pharmacother. 8: 75-94.
14. Ezzet, F., M. van Vugt, F. Nosten, et al 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents. Chemother. 44: 697-704.
15. Ashley, E.A., K. Stepniewska, N. Lindegardh, et al 2007. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health. 12: 201-208.
16. Lefèvre, G., P. Carpenter, C. Souppart, et al 2002. Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. J. Clin. Pharmacol. 42: 1147-1158.
17. Falade, C., M. Makanga, Z. Premji, et al 2005. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 99: 459-467.
18. van Vugt, M., P. Wilairatana, B. Gemperli, et al 1999. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 60: 936-942.
19. van Vugt, M., S. Looareesuwan, P. Wilairatana, et al 2000. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94: 545-548.
20. Lefèvre, G., S. Looareesuwan, S. Treeprasertsuk, et al 2001. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 64: 247-256.
21. Hatz, C., J. Soto, H.D. Nothdurft, et al 2008. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am. J. Trop. Med. Hyg. 78: 241-247.
22. Novartis. Data on file. 2010.
23. Arinaitwe, E., T.G. Sandison, H. Wanzira, et al 2009. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin. Infect. Dis. 49: 1629-1637.
24. Makanga, M. & S. Krudsood 2009. The clinical efficacy of artemether/lumefantrine (Coartem). Malar. J. 8(Suppl 1): S5.
25. Achan, J., J.K. Tibenderana, D. Kyabayinze, et al 2009. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 339: b2763.
26. Elamin, S.B., A.I. Awad, I.B. Eltayeb, et al 2010. Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Eur. J. Clin. Pharmacol. 66: 231-237.
27. Mens, P.F., P. Sawa, S.M. van Amsterdam, et al 2008. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar. J. 7: 237.
28. Sykes, A., I. Hendriksen, G. Mtove, et al 2009. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin. Infect. Dis. 49: 1195-1201.
29. Bassat, Q., M. Mulenga, H. Tinto, et al 2009. Dihydro-artemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS. One. 4: e7871.
30. Bell, D.J., D. Wootton, M. Mukaka, et al 2009. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar. J. 8: 204.
31. Ajayi, I.O., E.N. Browne, F. Bateganya, et al 2008. Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malar. J. 7: 190.
32. Faucher, J.F., A. Aubouy, A. Adeothy, et al 2009. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J. Infect. Dis. 200: 57-65.
33. Faye, B., A.T. Offianan, J.L. Ndiaye, et al 2010. Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop. Med. Int. Health. 15: 608-613.
34. Faye, B., J.L. Ndiaye, R. Tine, et al 2010. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am. J. Trop. Med. Hyg. 82: 140-144.
35. Kobbe, R., P. Klein, S. Adjei, et al 2008. A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malar. J. 7: 261.
36. Ndiaye, J.L., M. Randrianarivelojosia, I. Sagara, et al 2009. Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J. 8: 125.
37. Okafor, H.U., E.N. Shu & T. Oguonu 2010. Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. J. Trop. Pediatr. 56(6): 398-406.
38. Sagara, I., A. Diallo, M. Kone, et al 2008. A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am. J. Trop. Med. Hyg. 79: 655-661.
39. Sagara, I., S. Rulisa, W. Mbacham, et al 2009. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Malar. J. 8: 63.
40. Toure, O.A., L.K. Penali, J.D. Yapi, et al 2009. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote d'Ivoire. Malar. J. 8: 148.
41. Karunajeewa, H.A., I. Mueller, M. Senn, et al 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359: 2545-2557.
42. Valecha, N., P. Srivastava, S.S. Mohanty, et al 2009. Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malar. J. 8: 107.
43. Martensson, A., B. Ngasala, J. Ursing, et al 2007. Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. J. Infect. Dis. 195: 597-601.
44. Mayxay, M., M. Khanthavong, N. Lindegardh, et al 2004. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Clin. Infect. Dis. 39: 1139-1147.
45. Hutagalung, R., L. Paiphun, E.A. Ashley, et al 2005. A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malar. J. 4: 46.
46. van den Broek, I.V., U.A. Maung, A. Peters, et al 2005. Efficacy of chloroquine + sulfadoxine-pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh. Trans. R. Soc. Trop. Med. Hyg. 99: 727-735.
47. Makanga, M., Z. Premji, C. Falade, et al 2006. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am. J. Trop. Med. Hyg. 74: 991-998.
48. Piola, P., C. Fogg, F. Bajunirwe, et al 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 365: 1467-1473.
49. von Seidlein L., K. Bojang, P. Jones, et al 1998. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am. J. Trop. Med. Hyg. 58: 638-644.
50. Sutherland, C.J., R. Ord, S. Dunyo, et al 2005. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS. Med. 2: e92.
51. Falade, C. & C. Manyando 2009. Safety profile of Coartem: the evidence base. Malar. J. 8(Suppl. 1): S6.
52. Adjei, G.O., J.A. Kurtzhals, O.P. Rodrigues, et al 2008. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar. J. 7: 127.
53. Maiteki-Sebuguzi, C., P. Jagannathan, V.M. Yau, et al 2008. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar. J. 7: 106.
54. Nosten, F. & N.J. White 2007. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77(6 Suppl.): 181-192.
55. Whitty, C.J., S. Edmonds & T.K. Mutabingwa 2005. Malaria in pregnancy. BJOG 112: 1189-1195.
56. McGready, R., S.O. Tan, E.A. Ashley, et al 2008. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS. Med. 5: e253.
57. Piola, P., C. Nabasumba, E. Turyakira, et al 2010. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet. Infect. Dis. 10: 762-769.
58. Adam, I., E.M. Elhassan, E.M. Omer, et al 2009. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann. Trop. Med. Parasitol. 103: 205-210.
59. Manyando, C., R. Mkandawire, L. Puma, et al 2010. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar. J. 9: 249.
60. th NMCP Best Practice Sharing Workshop, 10-11 February 2010, Kigali, Rwanda.
61. Kabanywanyi, A.M., N. Mulure, C. Migoha, et al 2010. Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting. Malar. J. 9: 205.
62. Denis, M.B., R. Tsuyuoka, P. Lim, et al 2006. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health. 11: 1800-1807.
63. White, N.J. 2004. Antimalarial drug resistance. J. Clin. Invest. 113: 1084-1092.
64. Hastings, I.M., W.M. Watkins & N.J. White 2002. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357: 505-519.
65. Stepniewska, K. & N.J. White 2008. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents. Chemother. 52: 1589-1596.
66. Ashley, E.A., S. Krudsood, L. Phaiphun, et al 2004. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J. Infect. Dis. 190: 1773-1782.
67. Hung, T.Y., T.M. Davis, K.F. Ilett, et al 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57: 253-262.
68. Premji, Z.G., S. Abdulla, B. Ogutu, et al 2008. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar. J. 7: 244.
69. Borrmann, S., W.M. Sallas, S. Machevo, et al 2010. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop. Med. Int. Health. 15: 434-441.
70. Kabanywanyi, A.M., C. Lengeler, P. Kasim, et al 2010. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Malar. J. 9: 48.
71. Barnes, K.I., D.N. Durrheim, F. Little, et al 2005. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS. Med. 2: e330.
72. Zurovac, D., M. Ndhlovu, N. Sipilanyambe, et al 2007. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar. J. 6: 31.
73. Chizema-Kawesha, E., V.M. Mukonka, M. Mwanza, et al Evidence of substantial nationwide reduction of malaria cases and deaths due to scale-up of malaria control activities in Zambia, 2001-2008. World Health Organization, Zambia 19-23 January 2009. Impact Evaluation Mission Report. 2009.
74. Deployment of artemether-lumefantrine with rapid diagnostic tests at community level, Raya Valley, Tigray, Ethiopia. WHO Global Malaria Programme, June 2009. 1-6-2009.
75. Novartis Annual Report 2009. 2010.
76. Barrington, J., O. Wereko-Brobby, P. Ward, et al 2010. SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology. Malar. J. 9: 298.
77. Ogutu, B., A.B. Tiono, M. Makanga, et al 2010. Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? Malar. J. 9: 30.
78. Dunyo, S., P. Milligan, T. Edwards, et al 2006. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS. Clin. Trials. 1: e20.
79. El-Sayed, B., S.E. El-Zaki, H. Babiker, et al 2007. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS. One. 2: e1311.
80. Rottmann, M., C. McNamara, B.K. Yeung, et al 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329: 1175-1180.